Nina Radosevic‐Robin

3.9k total citations
55 papers, 1.3k citations indexed

About

Nina Radosevic‐Robin is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Nina Radosevic‐Robin has authored 55 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 18 papers in Cancer Research and 14 papers in Molecular Biology. Recurrent topics in Nina Radosevic‐Robin's work include Cancer Immunotherapy and Biomarkers (18 papers), Cancer Cells and Metastasis (11 papers) and HER2/EGFR in Cancer Research (11 papers). Nina Radosevic‐Robin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Cancer Cells and Metastasis (11 papers) and HER2/EGFR in Cancer Research (11 papers). Nina Radosevic‐Robin collaborates with scholars based in France, United States and Italy. Nina Radosevic‐Robin's co-authors include Frédérique Penault‐Llorca, Rea Bingula, Jean‐Yves Berthon, Edith Filaire, Marc Filaire, Marie‐Paule Vasson, Annick Bernalier‐Donadille, Anne Cayre, Xavier Durando and Fabrice Kwiatkowski and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Nina Radosevic‐Robin

53 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nina Radosevic‐Robin France 21 627 528 352 223 209 55 1.3k
Emmanuel Blot France 19 639 1.0× 543 1.0× 368 1.0× 207 0.9× 154 0.7× 50 1.4k
Andrew Redfern Australia 20 703 1.1× 732 1.4× 439 1.2× 262 1.2× 205 1.0× 102 1.6k
Katie M. Campbell United States 15 523 0.8× 547 1.0× 251 0.7× 204 0.9× 352 1.7× 38 1.2k
Wenjun Chang China 24 546 0.9× 764 1.4× 399 1.1× 348 1.6× 308 1.5× 65 1.7k
Tujana Boldanova Switzerland 16 335 0.5× 632 1.2× 577 1.6× 244 1.1× 215 1.0× 20 1.8k
Kazuyoshi Ohkawa Japan 29 710 1.1× 618 1.2× 299 0.8× 259 1.2× 526 2.5× 158 2.4k
Yalun Li China 18 352 0.6× 825 1.6× 577 1.6× 226 1.0× 101 0.5× 81 1.5k
Qian Wu China 20 383 0.6× 508 1.0× 285 0.8× 179 0.8× 213 1.0× 81 1.1k

Countries citing papers authored by Nina Radosevic‐Robin

Since Specialization
Citations

This map shows the geographic impact of Nina Radosevic‐Robin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Radosevic‐Robin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Radosevic‐Robin more than expected).

Fields of papers citing papers by Nina Radosevic‐Robin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Radosevic‐Robin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Radosevic‐Robin. The network helps show where Nina Radosevic‐Robin may publish in the future.

Co-authorship network of co-authors of Nina Radosevic‐Robin

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Radosevic‐Robin. A scholar is included among the top collaborators of Nina Radosevic‐Robin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Radosevic‐Robin. Nina Radosevic‐Robin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Ferrand, Nathalie, et al.. (2022). WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells. Cancers. 14(6). 1487–1487. 6 indexed citations
4.
Bidet, Yannick, et al.. (2022). Circulating proteins as predictive and prognostic biomarkers in breast cancer. Clinical Proteomics. 19(1). 25–25. 39 indexed citations
5.
Garambois, Véronique, Nelly Pirot, Charles Theillet, et al.. (2021). Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. mAbs. 13(1). 1914883–1914883. 7 indexed citations
6.
Guerrera, Ida Chiara, Alain Schmitt, Vincent Jung, et al.. (2021). STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway. Oncogene. 40(49). 6627–6640. 35 indexed citations
7.
Mezquita, Laura, Caroline Rossoni, Édouard Auclin, et al.. (2021). Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy. European Journal of Cancer. 145. 221–229. 53 indexed citations
8.
Durando, Xavier, Marie‐Ange Mouret‐Reynier, Myriam Kossaï, et al.. (2021). Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients. Frontiers in Oncology. 11. 678315–678315. 27 indexed citations
9.
Kossaï, Myriam, Nina Radosevic‐Robin, & Frédérique Penault‐Llorca. (2021). Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open. 6(5). 100257–100257. 22 indexed citations
10.
Mezquita, Laura, Caroline Rossoni, Édouard Auclin, et al.. (2019). MA25.03 Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients. Journal of Thoracic Oncology. 14(10). S351–S352. 2 indexed citations
11.
Bingula, Rea, Marc Filaire, Nina Radosevic‐Robin, et al.. (2018). Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma. Medicine. 97(50). e13676–e13676. 29 indexed citations
12.
Dauplat, Marie-Mélanie, et al.. (2018). Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer. 18(1). 129–129. 38 indexed citations
13.
Penault‐Llorca, Frédérique & Nina Radosevic‐Robin. (2018). Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view. Translational Lung Cancer Research. 7(5). 716–721. 11 indexed citations
14.
Leconet, Wilhem, Stanislas du Manoir, Clément Chevalier, et al.. (2016). Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clinical Cancer Research. 23(11). 2806–2816. 87 indexed citations
15.
Penault‐Llorca, Frédérique & Nina Radosevic‐Robin. (2016). Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nature Reviews Clinical Oncology. 13(8). 487–503. 40 indexed citations
16.
Chalabi, Nasséra, Catherine Abrial, Nina Radosevic‐Robin, et al.. (2015). Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Critical Reviews in Oncology/Hematology. 95(1). 88–104. 68 indexed citations
17.
Nucíforo, Paolo, Nina Radosevic‐Robin, Tony Ng, & Maurizio Scaltriti. (2015). Quantification of HER family receptors in breast cancer. Breast Cancer Research. 17(1). 53–53. 35 indexed citations
18.
Privat, Maud, Nina Radosevic‐Robin, Corinne Aubel, et al.. (2014). BRCA1 Induces Major Energetic Metabolism Reprogramming in Breast Cancer Cells. PLoS ONE. 9(7). e102438–e102438. 62 indexed citations
19.
Chêne, G., Nina Radosevic‐Robin, Anne Cayre, et al.. (2014). Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifen. European Journal of Histochemistry. 58(2). 2251–2251. 8 indexed citations
20.
Chêne, Geneviève, J Dauplat, Nina Radosevic‐Robin, Anne Cayre, & Frédérique Penault–Llorca. (2013). The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma. Bulletin du Cancer. 100(7-8). 757–764. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emmanuel Blot Breakdown of academic impact, for papers by Andrew Redfern Breakdown of academic impact, for papers by Katie M. Campbell Breakdown of academic impact, for papers by Wenjun Chang Breakdown of academic impact, for papers by Tujana Boldanova Breakdown of academic impact, for papers by Kazuyoshi Ohkawa Breakdown of academic impact, for papers by Yalun Li Breakdown of academic impact, for papers by Qian Wu
Rankless by CCL
2026